Liquidia (NASDAQ:LQDA) Director Sells $17,063,005.67 in Stock

Liquidia Corporation (NASDAQ:LQDAGet Free Report) Director Stephen Bloch sold 242,269 shares of the company’s stock in a transaction on Thursday, June 11th. The shares were sold at an average price of $70.43, for a total transaction of $17,063,005.67. Following the completion of the sale, the director directly owned 1,176,184 shares in the company, valued at $82,838,639.12. This trade represents a 17.08% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Liquidia Price Performance

LQDA stock opened at $71.23 on Monday. The firm’s fifty day simple moving average is $49.85 and its 200-day simple moving average is $40.96. The company has a market capitalization of $6.33 billion, a P/E ratio of 508.82 and a beta of 0.57. The company has a debt-to-equity ratio of 1.18, a current ratio of 2.22 and a quick ratio of 2.03. Liquidia Corporation has a 12 month low of $11.85 and a 12 month high of $72.71.

Liquidia (NASDAQ:LQDAGet Free Report) last posted its earnings results on Monday, May 11th. The company reported $0.52 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.41 by $0.11. Liquidia had a net margin of 7.74% and a return on equity of 46.82%. The firm had revenue of $132.87 million during the quarter, compared to analysts’ expectations of $119.44 million. Liquidia’s quarterly revenue was up 4187.1% on a year-over-year basis. As a group, equities research analysts forecast that Liquidia Corporation will post 2.97 earnings per share for the current year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on the stock. Weiss Ratings reiterated a “sell (d-)” rating on shares of Liquidia in a research note on Tuesday, April 21st. HC Wainwright boosted their target price on shares of Liquidia from $67.00 to $75.00 and gave the company a “buy” rating in a research note on Friday, June 5th. Jefferies Financial Group reiterated a “buy” rating and issued a $60.00 target price on shares of Liquidia in a research note on Monday, May 11th. Raymond James Financial reiterated a “strong-buy” rating and issued a $68.00 target price on shares of Liquidia in a research note on Thursday, June 4th. Finally, Lifesci Capital upgraded shares of Liquidia to a “strong-buy” rating in a research note on Thursday, March 5th. Three research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Sell rating to the company’s stock. According to MarketBeat, Liquidia has an average rating of “Moderate Buy” and an average price target of $60.29.

Check Out Our Latest Analysis on Liquidia

Hedge Funds Weigh In On Liquidia

Large investors have recently added to or reduced their stakes in the stock. Northwestern Mutual Wealth Management Co. acquired a new position in Liquidia during the fourth quarter worth $25,000. NewEdge Advisors LLC acquired a new position in Liquidia during the second quarter worth $25,000. Skandinaviska Enskilda Banken AB publ acquired a new position in Liquidia during the third quarter worth $30,000. FNY Investment Advisers LLC acquired a new position in Liquidia during the third quarter worth $34,000. Finally, Covestor Ltd raised its position in Liquidia by 41.9% during the fourth quarter. Covestor Ltd now owns 1,216 shares of the company’s stock worth $42,000 after acquiring an additional 359 shares during the period. 64.54% of the stock is currently owned by institutional investors and hedge funds.

Liquidia Company Profile

(Get Free Report)

Liquidia Technologies, Inc is a clinical-stage biopharmaceutical company headquartered in Research Triangle Park, North Carolina. The company leverages its proprietary PRINT® (Particle Replication In Non-wetting Templates) platform to engineer precisely shaped and sized drug particles, with the goal of improving delivery, efficacy and safety profiles. By controlling particle characteristics at the nanoscale, Liquidia seeks to enhance respiratory and other therapies that depend on targeted delivery.

The company’s lead product candidate, LIQ861, is a dry powder formulation of treprostinil designed for inhalation in patients with pulmonary arterial hypertension (PAH).

Featured Articles

Insider Buying and Selling by Quarter for Liquidia (NASDAQ:LQDA)

Receive News & Ratings for Liquidia Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Liquidia and related companies with MarketBeat.com's FREE daily email newsletter.